Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of azilsartan medoxomil + chlorthalidone fixed-dose combination in moderate to severe hypertension
2008-004218-28Phase 3Completed
- Sponsor
- Takeda
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in essential hypertension comparing Azilsartan medoxomil + chlorthalidone fixed-dose combination, Azilsartan medoxomil monotherapy and Chlorthalidone monotherapy (3 arms). Primary endpoint: Primary antihypertensive effect comparison. Started Jul 2009; status: completed.
02
Drugs
azilsartan medoxomilchlorthalidone
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2008-004218-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004218-28.